KETOPROFEN L-LYSINE FORMULATION IS GASTROPROTECTIVE FOR GASTRIC MUCOSA: POSITIVE IMPLICATION FOR DAMAGED GASTRIC EPITHELIUM
Ketoprofen, a NSAID, is widely used for its analgesic efficacy and tolerability. L-lysine salification was reported to increase the solubility and the gastric absorption and tolerance of Ketoprofen. The management of NSAIDs gastrotoxicity still represents a major limitation in prolonged therapies, mainly when gastric lesions are present, now, a new study from the Sbarro Health Research Organization (Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Temple University, Philadelphia PA USA), the biopharmaceutical company Dompé and the University of L’Aquila (Italy), investigated the gastro-protective activity of L-lysine by using a well-established model of gastric mucosa injury, the ethanol-gastric injury model. This finding published on J Cellular Physiology, may have important implications: “Our studies unravel the mechanism of L-lysine gastroprotection, by counteracting lipid peroxidation and upregulating a panel of key endogenous gastro-protective proteins. The data obtained indicate a gastroprotective effect of L-lysine on gastric mucosa integrity” say Prof. Annamaria Cimini of the University of L’Aquila and Dr. Marcello Allegretti, Chief Scientific Officer of Dompé Group, lead authors of the study. “For the first time it has provided significant insights on the mechanism underlying the reported lower gastrotoxicity of Ketoprofen L-Lysine Salt as compared to the non-salified form of the drug, suggesting the possible use of L-lysine for other drug formulations” says Prof. Antonio Giordano, founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University.